IO Biotech CEO after US failure: "It doesn't worry me"

A number of US pharmaceutical companies have stopped their trials with the enzyme IDO after a US company failed in phase 3, but it does not scare Danish IO Biotech that works with the same enzyme as the company has a different approach than the US companies.

Mai-Britt Zocca, CEO of IO Biotech. Photo: IO Biotech.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles